2014

Clinical Trial Results, Stock Movements, Grants & Donations, and Drug Resubmissions - Research Report on Gilead, WellPoint, Zoetis, Teleflex, and Orexigen Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, December 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), WellPoint Inc. (NYSE: WLP), Zoetis Inc. (NYSE: ZTS), Teleflex Incorporated (NYSE: TFX), and Orexigen Therapeutics, Inc. (NASDAQ: OREX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On December 18, 2013, Gilead Sciences Inc. (Gilead) announced topline results from three Phase 3 clinical trials (ION-1, ION-2, and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg and the NS5A inhibitor ledipasvir (LDV) 90 mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. According to the Company, out of the 1,518 patients randomized to the 12-week arms of ION-1 and to all arms of ION-2 and ION-3, 1,456 patients achieved the primary efficacy endpoint of SVR12, and of the 62 patients who failed to achieve SVR12, 36 patients experienced virologic failure. Norbert Bischofberger, PhD, Executive Vice President of Research and Development and Chief Scientific Officer, commented, "The results of the ION studies demonstrate that a simple, safe and short course of therapy with a single tablet regimen of sofosbuvir/ledipasvir can provide high cure rates among patients with genotype 1 HCV infection, while eliminating the need for both interferon and ribavirin. With the availability of these results, Gilead is finalizing its regulatory filing for sofosbuvir/ledipasvir, with the goal of submitting a New Drug Application in the first quarter of 2014." The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9898_GILD

--

WellPoint Inc. Research Report

On December 18, 2013, WellPoint Inc.'s (WellPoint) stock rose 2.45%, closing at $89.02. Over the previous three trading sessions, shares of WellPoint increased 1.45%, compared to the Dow Jones Industrial Average, which increased 2.62% during the same period. The Full Research Report on WellPoint Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/64cd_WLP

--

Zoetis Inc. Research Report

On December 17, 2013, Zoetis Inc. (Zoetis) reported that it is part of a consortium of 22 academic, industry and private enterprise organizations from 11 countries, which has been awarded the largest animal health grant in EU history for exploring new ways to ensure the sustainability of modern animal production. According to the press release available on the website of Newcastle University, the project, which was launched at Newcastle University, aims to explore ways to increase production quality, limit environmental impact and preserve profitability for the farmers, and those who live from animal food production. Executive Vice President of Zoetis and Area President Europe, Africa and Middle East region, Alejandro Bernal said, "This is a very synergistic partnership. All parties can benefit from the combined expertise and resource of what is probably the biggest poultry and pigs research network in the world at the moment. This is a great example of a private/public initiative to advance our scientific knowledge, respond to the challenges of the future for our world and improve animal health and welfare." The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7e25_ZTS

--

Teleflex Incorporated Research Report

On December 18, 2013, Teleflex Incorporated (Teleflex) announced that the Company donated $25,000 to the American Respiratory Care Foundation (ARCF) as part of its Purpose-Driven Trivia Challenge at the Teleflex booth during the American Association for Respiratory Care (AARC) Congress 2013. President, Anesthesia & Respiratory Division, Cary Vance commented, "The AARC Congress is the pinnacle of our year's engagement with the broader respiratory therapy community. In addition to hosting the Purpose-Driven Trivia Challenge, we enjoyed sharing updates on our portfolio of proven medical brands, products, and technologies, as well as sharing our approach to purpose-driven innovation with conference attendees." The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9c7d_TFX

--

Orexigen Therapeutics, Inc. Research Report

On December 11, 2013, Orexigen Therapeutics, Inc. (Orexigen) announced that it has resubmitted the Contrave® New Drug Application to the United States Food and Drug Administration (FDA). The Company informed that Contrave is being developed for weight loss and maintenance of weight loss. The Company also stated that the resubmission follows the November 25, 2013 announcement of the successful interim analysis of the Light Study, the Contrave cardiovascular outcomes trial, which is being conducted under a Special Protocol Assessment with the FDA. CEO Michael Narachi said, "This resubmission sets in motion the first of four potential key catalysts in 2014. With the successful Light Study interim analysis, we are confident in the prospect for approvals next year in the United States and in Europe. If Contrave is approved, we look forward to a well-executed U.S. launch by Takeda. Additionally, we anticipate making progress next year in our discussions with potential partners for Contrave for territories outside North America." The Company added that the interim analysis clinical study report will be provided to the FDA within 60 days of the NDA resubmission, and review period for the resubmission is expected to be six months. The Full Research Report on Orexigen Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1b1a_OREX

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.